| AEPCX | TIOHX | AEPCX / TIOHX | |
| Total Expense Ratio | 1.58 | 0.68 | 232% |
| Annual Report Gross Expense Ratio | 1.58 | 0.68 | 232% |
| Fund Existence | 26 years | 11 years | - |
| Gain YTD | 4.674 | 7.748 | 60% |
| Front Load | N/A | N/A | - |
| Min. Initial Investment | 250 | 100000 | 0% |
| Min. Initial Investment IRA | N/A | N/A | - |
| Net Assets | 140B | 2.61B | 5,364% |
| Annual Yield % from dividends | 2.07 | 1.85 | 112% |
| Returns for 1 year | 0.91 | 4.42 | 21% |
| Returns for 3 years | 23.76 | 34.67 | 69% |
| Returns for 5 years | -8.74 | -6.58 | 133% |
| Returns for 10 years | 37.24 | 87.76 | 42% |
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| JETS | 28.22 | 0.05 | +0.18% |
| U.S. Global Jets ETF (JETS) | |||
| TOCT | 27.23 | N/A | N/A |
| Innovator 2 Yr to October 2027 (TOCT) | |||
| CANC | 41.65 | -0.36 | -0.86% |
| Tema Oncology ETF (CANC) | |||
| EASY | 26.33 | -0.25 | -0.93% |
| Liberty One Defensive Dividend Growth ETF (EASY) | |||
| XBI | 156.72 | -1.53 | -0.97% |
| State Street SPDR S&P Biotech ETF (XBI) | |||